WHAT’S NEW?

Prospective Phase: the second year of observation will be over in December, 2018. Data present into database must be confirmed by sites before starting the analysis

3 posters related to 3WINTERS-IPS preliminary data (cut-off 22 months of observation) have been presented at ASH Congress in San Diego, (CA), USA (1 – 4 December, 2018)

201 of 210 VWD3 centrally-confirmed patients are being observed during the prospective phase of the study


TYPE 3 VON WILLEBRAND INTERNATIONAL REGISTRIES INHIBITOR PROSPECTIVE STUDY
(3WINTERS-IPS)

A 5-year International Registries and Prospective Study on VWD Type 3

Scientific Coordination and Supervision:

A.B. FEDERICI & P.M. MANNUCCI

With the participation of the Working Group on VWD3 recognized by the European Association of Haemophilia and Allied Disorders (EAHAD) and the Sub-Committee on VWF Scientific Standardization Committees of the International Society on Thrombosis and Haemostasis (SC-VWF, SSC-ISTH)


For any urgent request please contact the Scientific Coordinator Professor A.B. Federici to the following

e-mail address:

augusto.federici@unimi.it





Published on 10 August 2011
Copyright © of Sintesi Research Srl Soc. Unipersonale, Via M. Bandello, 6 - 20123 Milano, Italy
sabato 14 dicembre 2019 Ver. 1.7.0